MariMed Q1 revenue up 27% to $31.3M; adj EBITDA $10.4M, guidance reaffirmed

MARIMED INC.

2022-Q1 EPS reported $0.01 revenue$31,282,000

Revenue $31.3M (up 27% YoY); gross margin 54.3% vs 53.5%; net income $4.2M (flat YoY).
Non-GAAP adjusted EBITDA $10.4M (+29% YoY); cash from operations $8.5M; working capital $20.1M.
Closed Maryland and Illinois acquisitions post-quarter; plans CSE listing to boost liquidity.
FY 2022 guidance held: revenue $145-150M, gross margin 54-55%, adj EBITDA $47-52M, capex ~$25M.
Retail dispensary revenue grew 41% YoY; wholesale up 6%; launched THC-infused drink mixes in MA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.